Hi, what are you looking for?
Almirall, a pharmaceutical firm based in Spain, ended 2025 with a net profit of €46.2 million, which was 357% more than its 2024 profit...
Vanda Pharmaceuticals (NASDAQ: VNDA) opened some 45% higher today after the biotech firm said it has received the FDA’s approval for its treatment of...
Nvidia stock (NASDAQ: NVDA) ticked higher on Monday as Wall Street headed into the chipmaker’s Feb. 25 earnings report with expectations already sky-high. The...
Could US President Donald Trump’s renewed push to acquire Greenland — by purchase or force — mark a breaking point for NATO’s 77-year-old alliance?...
A major purchase of Canadian canola by a Chinese importer following Prime Minister Mark Carney’s recent trip to Beijing has energised Canadian farmers’ prospects...
Artificial intelligence (AI) was mostly a story of GPUs in 2025 – but analysts now say the spotlight is shifting. According to T. Rowe...
Advanced Micro Devices (NASDAQ: AMD stock) projects that if its ambitious data-center expansion targets materialize, shareholders could see massive upside through 2030. The claim...
Netflix is preparing to report its fourth-quarter fiscal 2025 earnings after the market closes on Tuesday, January 20, with investors focused on whether the...
Oil prices face mounting fundamental pressure as potential shifts in global oversupply dynamics emerge, driven by China’s decelerating stockpiling, which is tied to the...
US stocks ticked higher at midday Friday as the S&P 500 climbed 0.3%, the Nasdaq advanced 0.4%, and the Dow Jones Industrial Average added...
“GLP-1 drugs don’t just change what people eat,” Karthik Srinivasan, communications strategy consultant, tells Invezz. They change whether people want to eat at all....
Indian stocks, especially the nation’s tech sector, will likely face turbulence in the first half of 2026, according to Amish Shah, a senior Bank...
The Trump administration on Thursday unveiled what it called the “Great Healthcare Plan,” a broad framework aimed at addressing healthcare affordability, drug prices, and...